secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-01-27T23:59:59+00:00
Accession:  0000950170-25-008995
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd submits XEC variant data to FDA supporting pemivibart treatment EUA amendment
--------------------------------------------------------------------------------

- Updated immunobridging analysis with XEC variant shows pemivibart titers substantially exceed adintrevimab in Days 0-5.
- Adintrevimab previously showed 66-74% risk reduction in hospitalization/death vs placebo in STAMP trial.
- No additional anaphylaxis reports during post-authorization use of PEMGARDA for COVID-19 PrEP to date.
- Submission consistent with prior analyses since July 2024; FDA review ongoing with no statutory deadline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025008995/0000950170-25-008995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025008995/ivvd-20250127.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-008995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer